Nine large pharma companies have reached agreements with the Trump administration to lower certain drug prices in the U.S. | ...
Nine drug manufacturers will offer their drugs to Medicaid recipients at most-favored-nation discounts in exchange for tariff ...
Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...
Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...
Reimbursement policy in the US saw major upheaval in the second half of 2025. New mandates, stalled subsidy negotiations, and pricing pressures created major uncertainty for payers, providers, and ...
To access our top 5 gated pieces of 2025, however, readers must first tell us a little bit about themselves.
On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U ...
A hedge fund with an integral role in Yellow Corp.’s bankruptcy proceedings is pushing for shareholders to have a bigger say in the company’s upcoming liquidation. MFN Partners, which amassed a more ...
The largest holder of Yellow Corp. shares has asked the company’s directors to fill two vacant board seats and set up a special pay plan to keep around executives and others to sell off assets under ...
Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "MFN reinforces the worst incentives in 340B, shifts costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback